Through the above study, we hope to further explore the pathogenesis of non-segmental vitiligo and clarify whether rosiglitazone, a PPAR-specific agonist, can promote melanocyte proliferation and pigmentation through up-regulation of PPAR pathways, providing reference ideas for the search of new potential vitiligo therapeutic agents. Here, PPARA is linked to vitiligo.